CTAD: TauRx Touts Candidate Safety as Anavex Stumbles over Potential Data Error
02 Dec 2022
Clinical ResultPhase 3
Courtesy Getty Images
As the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference continues, TauRx Pharmaceuticals and Anavex Life Sciences presented positive data from their alternatives to the anti-amyloid approach.
TauRx's Oral Candidate Shows Strong Safety Pro >
Based in Scotland and Singapore, TauRx is developing hydromethylthionine mesylate (HMTM), which targets Tau pathology in Alzheimer’s. While patients on Biogen's Aduhelm face bi-weekly injections, HMTM is an oral candidate with a strong safety profile.
Phase III data released in October showed HMTM significantly slowed cognitive and brain atrophy compared to historical controls TauRx reported. The company faced challenges with the placebo group, so data from publicly available placebo arms from other AD trials were used to prove efficacy.
During its CTAD presentation, TauRx shared topline data from the trial that showed sustained improvement in cognition over 18 months over pre-treatment levels in participants with mild cognitive impairment.
According to the press release, “sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied.”
A data scrape by the Alzheimer’s Association in January showed 143 agents currently in clinical trials for AD.
A unique aspect of HMTM is its safety profile. The drug showed no risk of amyloid-related imaging abnormalities (ARIA), a side effect seen in nearly 40% of AD patients taking Aduhelm in Biogen’s Phase III studies.
Armed with efficacy data, a robust safety pro convenient oral dosing, TauRx is prepping for regulatory submissions in the U.K., U.S. and Canada.
Anavex's Positive Data Marred by Mathematical Slip
Anavex Life Sciences is attempting to treat the mild cognitive impairment associated with Alzheimer's disease via a small molecule activator of the sigma-1 receptor (SIGMAR1).
Research suggests SIGMAR1 is to be pivotal to promote neuroplasticity and restore homeostasis in neural cells.
Anavex announced that patients treated with its SIGMAR1 activator, ANAVEX2-73 (blarcamesine), were 84% more likely to have improved cognition scores of –0.50 points or better compared to patients on placebo. On average, the patients who saw gains showed improvement of –4.03 points, a difference considered significant.
However, Anavex is facing some suspicion over trial results. In the press release, the biopharma reported the drug led to a 45% slower rate of decline compared to placebo patients. But Investor’s Business Daily reported that a math error in the CTAD presentation indicated the drug may have slowed cognition by 33% instead.
According to Edward Hammond, CMO of Anavex, the company plans to “discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX 2-73 in this indication."
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.